糖尿病与肿瘤_West China Medical Journal

Authors：

康馨 ,  冉兴无

Corresponding author：

冉兴无, Email: vitamincc113@yahoo.com.cn

Keywords：

糖尿病; 肿瘤; 进展

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　糖尿病与肿瘤均为常见病，两者之间的关系一直存在争论。早在20世纪30年代就有学者提出糖尿病与肿瘤发生有关。但直到最近10年，才有许多临床流行病学、观察性研究以及队列研究的证据显示糖尿病与肿瘤相关。两者之间的生物学联系包括高胰岛素血症、炎性细胞因子、生长因子等，糖尿病患者不同的治疗方案对肿瘤发生风险存在影响。现就近年来有关糖尿病与肿瘤关系的研究进展做一综述。

Citation： 康馨,冉兴无. 糖尿病与肿瘤. West China Medical Journal, 2011, 26(6): 857-862. doi: Copy

1.	Wilson EB, Maher HC. Cancer and tuberculosis with some comments on cancer and other diseases[J]. Am J Cancer, 1932, 16(2): 227-250.
2.	Chowdhury TA. Diabetes and cancer[J]. QJM, 2010, 103(12): 905-915.
3.	Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan[J]. Arch Intern Med, 2006, 166(17): 1871-1877.
4.	Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women[J]. JAMA, 2005, 293(2): 194-202.
5.	Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140 000 adults in Austria[J]. Diabetologia, 2006, 49(5): 945-952.
6.	Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk[J]. Diabetes Care, 2007, 30(3): 561-567.
7.	Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2: an independent risk factor for cancer?[J]. Exp Clin Endocrinol Diabetes, 2010, 118(1): 4-8.
8.	Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer[J]. Endocr Relat Cancer, 2009, 16(4): 1103-1123.
9.	Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(11): 2056-2062.
10.	Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study[J]. Br J Cancer, 2005, 92(11): 2070-2075.
11.	Zendehdel K, Nyrén O, Ostenson CG, et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden[J]. J Natl Cancer Inst, 2003, 95(23): 1797-1800.
12.	Shu X, Ji J, Li X, et al. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden[J]. Diabet Med, 2010, 27(7): 791-797.
13.	Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis[J]. Diabetologia, 2007, 50(7): 1365-1374.
14.	Khaw KT, Wareham N, Bingham S, et al. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(6): 915-919.
15.	Lipscombe LL, Goodwin PJ, Zinman B, et al. The impact of diabetes on survival following breast cancer[J]. Breast Cancer Res Treat, 2008, 109(2): 389-395.
16.	Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis[J]. Dig Dis Sci, 2010, 55(7): 1839-1851.
17.	Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis[J]. JAMA, 2008, 300(23): 2754-2764.
18.	Siddiqui AA, Maddur H, Naik S, et al. The association of elevated HbA1c on the behavior of adenomatous polyps in patients with type-II diabetes mellitus[J]. Dig Dis Sci, 2008, 53(4): 1042-1047.
19.	Barone BB, Yeh HC, Snyder CF, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis[J]. Diabetes Care, 2010, 33(4): 931- 939.
20.	Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis[J]. J Natl Cancer Inst, 2005, 97(22): 1679-1687.
21.	Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101.
22.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4): 225-249.
23.	Pinheiro SP, Holmes MD, Pollak MN, et al. Racial differences in premenopausal endogenous hormones[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(9): 2147-2153.
24.	Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis[J]. Lancet Oncol, 2008, 9(11): 1039-1047.
25.	Kushi LH, Byers T, Doyle C, et al. American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity[J]. CA Cancer J Clin, 2006, 56(5): 254-281.
26.	Barclay AW, Petocz P, McMillan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies[J]. Am J Clin Nutr, 2008, 87(3): 627-637.
27.	Lee IM. Physical activity and cancer prevention-data from epidemiologic studies[J]. Med Sci Sports Exerc, 2003, 35(11): 1823-1827.
28.	Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study[J]. Diabetes Care, 1997, 20(4): 537-544.
29.	Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study[J]. Lancet, 2008, 371(9626): 1783-1789.
30.	Stout RW, Vallance-Owen J. Insulin and atheroma[J]. Lancet, 1969, 1(7605): 1078-1080.
31.	Heuson JC, Legros N. Effect of insulin and of alloxan diabetes on growth of the rat mammary carcinoma in vivo[J]. Eur J Cancer, 1970, 6(4): 349-351.
32.	Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I[J]. Proc Nutr Soc, 2001, 60(1): 91-106.
33.	Wu Y, Yakar S, Zhao L, et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis[J]. Cancer Res, 2002, 62(4): 1030-1035.
34.	Kari FW, Dunn SE, French JE, et al. Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction[J]. J Nutr Health Aging, 1999, 3(2): 92-101.
35.	Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk[J]. Growth Horm IGF Res, 2004, 14(4): 261-269.
36.	Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials[J]. Diabetologia, 2011, 54(1): 25-31.
37.	Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study[J]. Diabetologia, 2009, 52(9): 1732-1744.
38.	Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group[J]. Diabetologia, 2009, 52(9): 1755-1765.
39.	Jonasson JM, Ljung R, Talbäck M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden[J]. Diabetologia, 2009, 52(9): 1745-1754.
40.	Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes[J]. Diabetologia, 2009, 52(9): 1766-1777.
41.	Origin Trial Investigators, Gerstein H, Yusuf S, et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)[J]. Am Heart J, 2008, 155(1): 26-32.
42.	Edwards KL, Riche DM, Stroup JS, et al. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy[J]. Pharmacotherapy, 2010, 30(9): 955-965.
43.	Dejgaard A, Lynggaard H, Råstam J, et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis[J]. Diabetologia, 2009, 52(12): 2507-2512.
44.	Chong CR, Chabner BA. Mysterious metformin[J]. Oncologist, 2009, 14(12): 1178-1181.
45.	Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis[J]. Cancer Prev Res (Phila), 2010, 3(11): 1451-1461.
46.	Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients[J]. BMJ, 2005, 330(7503): 1304-1305.
47.	Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, et al. Is it time to test metformin in breast cancer clinical trials?[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(3): 701-705.
48.	Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin[J]. Diabetes Care, 2006, 29(2): 254-258.
49.	Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study[J]. Acta Diabetol, 2009, 46(4): 279-284.
50.	Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes[J]. J Clin Oncol, 2007, 25(12): 1476-1481.
51.	Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents[J]. Pharmacoepidemiol Drug Saf, 2007, 16(5): 485-492.
52.	Monami M, Lamanna C, Marchionni N, et al. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials[J]. Diabetes Care, 2008, 31(7): 1455-1460.
53.	Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report[J]. CA Cancer J Clin, 2010, 60(4): 207-221.

1. 　Wilson EB, Maher HC. Cancer and tuberculosis with some comments on cancer and other diseases[J]. Am J Cancer, 1932, 16(2): 227-250.
2. 　Chowdhury TA. Diabetes and cancer[J]. QJM, 2010, 103(12): 905-915.
3. 　Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan[J]. Arch Intern Med, 2006, 166(17): 1871-1877.
4. 　Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women[J]. JAMA, 2005, 293(2): 194-202.
5. 　Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140 000 adults in Austria[J]. Diabetologia, 2006, 49(5): 945-952.
6. 　Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk[J]. Diabetes Care, 2007, 30(3): 561-567.
7. 　Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2: an independent risk factor for cancer?[J]. Exp Clin Endocrinol Diabetes, 2010, 118(1): 4-8.
8. 　Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer[J]. Endocr Relat Cancer, 2009, 16(4): 1103-1123.
9. 　Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(11): 2056-2062.
10. 　Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study[J]. Br J Cancer, 2005, 92(11): 2070-2075.
11. 　Zendehdel K, Nyrén O, Ostenson CG, et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden[J]. J Natl Cancer Inst, 2003, 95(23): 1797-1800.
12. 　Shu X, Ji J, Li X, et al. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden[J]. Diabet Med, 2010, 27(7): 791-797.
13. 　Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis[J]. Diabetologia, 2007, 50(7): 1365-1374.
14. 　Khaw KT, Wareham N, Bingham S, et al. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(6): 915-919.
15. 　Lipscombe LL, Goodwin PJ, Zinman B, et al. The impact of diabetes on survival following breast cancer[J]. Breast Cancer Res Treat, 2008, 109(2): 389-395.
16. 　Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis[J]. Dig Dis Sci, 2010, 55(7): 1839-1851.
17. 　Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis[J]. JAMA, 2008, 300(23): 2754-2764.
18. 　Siddiqui AA, Maddur H, Naik S, et al. The association of elevated HbA1c on the behavior of adenomatous polyps in patients with type-II diabetes mellitus[J]. Dig Dis Sci, 2008, 53(4): 1042-1047.
19. 　Barone BB, Yeh HC, Snyder CF, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis[J]. Diabetes Care, 2010, 33(4): 931- 939.
20. 　Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis[J]. J Natl Cancer Inst, 2005, 97(22): 1679-1687.
21. 　Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101.
22. 　Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4): 225-249.
23. 　Pinheiro SP, Holmes MD, Pollak MN, et al. Racial differences in premenopausal endogenous hormones[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(9): 2147-2153.
24. 　Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis[J]. Lancet Oncol, 2008, 9(11): 1039-1047.
25. 　Kushi LH, Byers T, Doyle C, et al. American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity[J]. CA Cancer J Clin, 2006, 56(5): 254-281.
26. 　Barclay AW, Petocz P, McMillan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies[J]. Am J Clin Nutr, 2008, 87(3): 627-637.
27. 　Lee IM. Physical activity and cancer prevention-data from epidemiologic studies[J]. Med Sci Sports Exerc, 2003, 35(11): 1823-1827.
28. 　Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study[J]. Diabetes Care, 1997, 20(4): 537-544.
29. 　Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study[J]. Lancet, 2008, 371(9626): 1783-1789.
30. 　Stout RW, Vallance-Owen J. Insulin and atheroma[J]. Lancet, 1969, 1(7605): 1078-1080.
31. 　Heuson JC, Legros N. Effect of insulin and of alloxan diabetes on growth of the rat mammary carcinoma in vivo[J]. Eur J Cancer, 1970, 6(4): 349-351.
32. 　Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I[J]. Proc Nutr Soc, 2001, 60(1): 91-106.
33. 　Wu Y, Yakar S, Zhao L, et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis[J]. Cancer Res, 2002, 62(4): 1030-1035.
34. 　Kari FW, Dunn SE, French JE, et al. Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction[J]. J Nutr Health Aging, 1999, 3(2): 92-101.
35. 　Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk[J]. Growth Horm IGF Res, 2004, 14(4): 261-269.
36. 　Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials[J]. Diabetologia, 2011, 54(1): 25-31.
37. 　Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study[J]. Diabetologia, 2009, 52(9): 1732-1744.
38. 　Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group[J]. Diabetologia, 2009, 52(9): 1755-1765.
39. 　Jonasson JM, Ljung R, Talbäck M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden[J]. Diabetologia, 2009, 52(9): 1745-1754.
40. 　Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes[J]. Diabetologia, 2009, 52(9): 1766-1777.
41. 　Origin Trial Investigators, Gerstein H, Yusuf S, et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)[J]. Am Heart J, 2008, 155(1): 26-32.
42. 　Edwards KL, Riche DM, Stroup JS, et al. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy[J]. Pharmacotherapy, 2010, 30(9): 955-965.
43. 　Dejgaard A, Lynggaard H, Råstam J, et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis[J]. Diabetologia, 2009, 52(12): 2507-2512.
44. 　Chong CR, Chabner BA. Mysterious metformin[J]. Oncologist, 2009, 14(12): 1178-1181.
45. 　Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis[J]. Cancer Prev Res (Phila), 2010, 3(11): 1451-1461.
46. 　Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients[J]. BMJ, 2005, 330(7503): 1304-1305.
47. 　Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, et al. Is it time to test metformin in breast cancer clinical trials?[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(3): 701-705.
48. 　Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin[J]. Diabetes Care, 2006, 29(2): 254-258.
49. 　Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study[J]. Acta Diabetol, 2009, 46(4): 279-284.
50. 　Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes[J]. J Clin Oncol, 2007, 25(12): 1476-1481.
51. 　Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents[J]. Pharmacoepidemiol Drug Saf, 2007, 16(5): 485-492.
52. 　Monami M, Lamanna C, Marchionni N, et al. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials[J]. Diabetes Care, 2008, 31(7): 1455-1460.
53. 　Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report[J]. CA Cancer J Clin, 2010, 60(4): 207-221.

West China Medical Journal

糖尿病与肿瘤

Abstract Full text Figures/Tables Video References Cited by

Format

Content